Gas Used at Baxter Plant Draws Attention

Gary Beck doesn’t know for certain if his multiple myeloma is linked to his neighbor, a Baxter International plant just blocks away in Mountain Home.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news

Related Links:

Publication date: Available online 5 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Josep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, Cristina Gil, José González-Campos, Pere Barba, María-Luz Amigo, María-José Moreno, Esperanza Lavilla, Natalia Alonso, Juan-Miguel Bergua, Mar Tormo, Jordi Ribera, Magdalena Sierra, Daniel Martínez-Carballeira, Santiago Mercadal, Jesús-María Hernández-Rivas, Ferran Vall-llovera, Eulàlia Genescà, Antònia Cladera
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ACS NanoDOI: 10.1021/acsnano.9b09618
Source: ACS Nano - Category: Nanotechnology Authors: Source Type: research
The objective of the current study was to evaluate the relevance and credibility of published NMA and unanchored MAIC studies aiming to estimate the comparative efficacy of treatment options for RRMM.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
In a series of 72 older and elderly frail patients (Charlson Comorbidity Index ≥4) with Philadelphia chromosome-negative ALL prospectively treated with very attenuated chemotherapy regimen (vincristine, dexamethasone, methotrexate and mercaptopurine) the rate of complete remission was 54%, with overall survival probability of 7.6 months. Patients with ECOG score
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Some readers have recently been asking me about curcumin and Covid-19. Is it good or bad to be taking it if you contract coronavirus?  Can it reduce your risk of contracting Covid-19? (See my post on vitamina D, incidentally.) I don’t know. If I had any answers, believe me, I’d be publishing them…immediately. Well, it just so happens that this afternoon I read a very interesting Science Daily article that may shed some light on this matter. It discusses the case study of ONE myeloma patient, in Wuhan, who was given an immunosuppressant drug, a monoclonal antibody, called tocilizumab. Here’s th...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll curcumin myeloma tocilizumab Source Type: blogs
This article reviews, in a systematic, organ-based approach, the acute metabolic and mechanical emergencies encountered in the emergency department in patients with hematologic malignancies.
Source: Contemporary Diagnostic Radiology - Category: Radiology Tags: ARTICLE Source Type: research
CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Authors: Allegra A, Innao V, Allegra AG, Pulvirenti N, Pugliese M, Musolino C Abstract Protease inhibitors (PIs) inhibit HIV‑1 and HIV‑2 proteases, impeding virus replication and liberation of viral elements from infected cells. In human immunodeficiency virus (HIV) subjects receiving PI‑based treatment, an impressive decrease in the amount of HIV‑associated cancers, unconnected to viral burden or CD4 amount was observed. Research has reported that PIs have influence on cancer proliferation, spread, and survival as an effect on endoplasmic reticulum stress, proteasome, NF‑κB and Akt signalling....
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
AbstractMultiple myeloma (MM) is a challenging, progressive, and highly heterogeneous hematological malignancy. MM is characterized by multifocal proliferation of neoplastic plasma cells in the bone marrow (BM) and sometimes in extramedullary organs. Despite the availability of novel drugs and the longer median overall survival, some patients survive more than 10  years while others die rapidly. This heterogeneity is mainly driven by biological characteristics of MM cells, including genetic abnormalities. Disease progressions are mainly due to the inability of drugs to overcome refractory disease and inevitable drug-r...
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
AbstractThese are the results of phase II study of bortezomib-melphalan-prednisolone (VMP) induction therapy followed by lenalidomide-dexamethasone (Rd) consolidation and lenalidomide maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), overall response rates (ORRs), and safety. Eighty-three eligible patients were enrolled between October 2012 and August 2014. The median PFS was 28.0  months (95% CI 19.6–36.7) and the median OS was 55.3 months (95% CI 51.6&nd...
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: American Health | Health Management | Myeloma